Septerna, Inc. Common Stock (SEPN NASDAQ) stock market data APIs
$24.0661
0.58(2.4%)
as of May 7, 2026
Try our APIs with
free plan!
Septerna, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Prev. Close
24.0661
Open
24.6492
High
25.2148
Low
23.5198
52 wk Range
6.44-32.63
Market Cap
1 078 M
Shares Outstanding
44 949 K
Revenue
45 951 K
EPS
-0.24
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Septerna, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Septerna, Inc. Common Stock data using free add-ons & libraries
Get Septerna, Inc. Common Stock Fundamental Data
Septerna, Inc. Common Stock Fundamental data includes:
- Net Revenue: 45 951 K
- EBITDA: -79 193 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Septerna, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-26
- EPS/Forecast: -0.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Septerna, Inc. Common Stock News
New
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.8 per share a year ago. These figures...
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock
Nuvation Bio Inc. (NYSE:NUVB) is one of the 12 Best Stocks to Buy According to Billionaire David Abrams. Nuvation Bio Inc. (NYSE:NUVB) has been featured in the 13F portfolio of Abrams Capital Managem...
Septerna Reports Positive Phase 1 Data For SEP-631; Plans Phase 2 In CS Urticaria
(RTTNews) - Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering small-molecule therapies targeting G protein-coupled receptors (GPCRs), announced positive results from its Phase 1...
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses...
Get Septerna, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
